Comparison of a Totally Implantable Access Device for Chemotherapy (Port-A-Cath) and Long-term Percutaneous Catheterization (Broviac)*

Greene, Frederick L.; Moore, Wesley S.; Strickland, G F; McFarland, James A.

doi:10.1097/00007611-198805000-00010

Cited by 57 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In several retrospective studies, external devices were associated with higher infection rates compared to TIVAPs in selected patient populations [33][34][35][36][37]. Groeger et al reported TIVAPs to be associated with fewer infections when compared to external catheters [38], with the septic events responding most often to administration of appropriate antibiotics, although removal of the port was necessary for persistent or recurrent bacteraemia or for fungal infections in some cases [36,39,40].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally Taxbro et al noted in a prospective study that their major findings included a possible low complication rate being achieved by applying evidence-based guidelines concerning the implantation of the ports and also the care of these subcutaneous vascular access ports [44]. Thrombosis is considered a frequent complication associated with central venous access devices, and there have also been some reports of right atrial thrombi and pulmonary emboli related to implanted ports [34,[45][46][47][48]. We recorded 4/1,000 (0.4 %) incidences of thrombosis, with all 4 patients having received chemotherapy via the port before thrombosis occurred.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

1000 Port‐A‐Cath^® Placements by Subclavian Vein Approach: Single Surgeon Experience

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

1000 Port‐A‐Cath^® Placements by Subclavian Vein Approach: Single Surgeon Experience

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The introduction of totally implantable venous access devices (TIVAD), also known as "ports", has provided a solution to this problem. They were originally used in cancer patients for the administration of chemotherapy and, compared with long-term percutaneous catheters, were shown to have reduced rates of catheter sepsis [1].…”

mentioning

confidence: 99%

Totally implantable venous access devices in cystic fibrosis: complications and patients' opinions

Rodgers¹,

Liddle²,

Nixon³

et al. 1998

Eur Respir J

View full text Add to dashboard Cite

The introduction of totally implantable venous access devices (TIVAD) has provided a solution to difficult venous access in patients with cystic fibrosis. Early reports have, however, recognized a number of complications with their use. We report our experience with five devices used over 8 yrs with regard to complications and patient attitudes. Patients' notes were reviewed to record the details of TIVAD insertion, duration of function, and complications. In January 1996 the surviving 30 patients were surveyed on their attitudes to TIVAD and complications by written questionnaire. Sixty one ports were implanted in 42 patients (aged 16-47 yrs) between June 1988 and January 1996, giving a total of 1,510 patient-months' experience. The duration of function ranged from 2 weeks to 6 yrs. Survival analysis showed that the median survival of ports was 53 months, 42 out of 61 (69%) had not failed in service at the end of follow-up or patient death. Twenty-three complications occurred in 19 patients. These included: line occlusion (10 patients), venous thrombosis (4), difficult access (3), infection (2), cellulitis (1), inversion of port chamber (2) and pneumothorax (1). The questionnaire showed that patients had strong views on the positioning of their port. Lifestyle issues included interference with seatbelts (8 patients), sport (4), clothing (2), sexual relations (2) and cosmetic appearance (15). Complication rates were similar to those in other studies, although infection rates and salvage of an occluded port were lower. The survey highlighted a number of lifestyle issues, with cosmetic appearance deemed unsatisfactory by half of the patients. However, the majority (28 out of 30) believed their totally implantable venous access devices to be a better alternative to cannulae or long lines.

show abstract

“…13,14 Nevertheless port systems have been shown to provide stable venous access beyond day 100 15 with a rate of infection and thrombosis comparable to external vascular access devices even in patients with leukemia. 2,[16][17][18][19] Ports were shown to provide longer failurefree function than Hickman and Broviac catheters. 15 The feasibility of prolonged and durable central venous access in a dog model of myeloablative BMT has been shown by Dennis et al 20 While there are reports on single lumen ports in patients with leukemia, 21 no data on the prospective use of port devices in patients receiving allogeneic blood stem cell transplantation have been published.…”

Section: Discussionmentioning

confidence: 99%

Double lumen port access in patients receiving allogeneic blood stem cell transplantation

Platzbecker

Illmer

Schaich

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:We performed a prospective trial investigating the feasibility of a double lumen port access in 26 patients with hematological malignancies or solid tumors receiving either standard conditioning (n ‫؍‬ 9, median age 49 years (range 19-65)) or dose-reduced conditioning (n ‫؍‬ 17, median age 56 years (range 35-66)) followed by allogeneic blood stem cell transplantation. The port system was implanted within 3 months (n ‫؍‬ 20, range 7-91 days) before transplantation or as indicated at different time points after transplantation (n ‫؍‬ 6, range 28-680 days). Most infusions, including the graft itself and all blood drawings, were performed via the port. Over a cumulative duration of 5622 days (1310 days after standard conditioning (range 56-349) and 4431 days after dose-reduced conditioning (range 49-489)) two port systems of patients receiving standard conditioning were removed due to early postimplantation pocket infection on day 6 and 8 after insertion, respectively. In the dose-reduced conditioning group only one late removal (day 287) of a port was required. Most of the patients in both groups reported less pain and a higher degree of comfort compared to peripheral or central venipuncture. The use of double lumen port access during conditioning and in an outpatient setting after allogeneic hemopoietic stem cell transplantation is feasible and advantageous for both patient and medical staff. Implantation several weeks before the start of conditioning might help in avoiding early infectious complications after conventional myeloablative conditioning. Bone Marrow Transplantation (2001) 28, 1067-1072. Keywords: double lumen port; allogeneic; dose-reduced conditioning Dose-reduced conditioning (DRC) followed by allogeneic stem cell transplantation (SCT) is increasingly performed

show abstract

Comparison of a Totally Implantable Access Device for Chemotherapy (Port-A-Cath) and Long-term Percutaneous Catheterization (Broviac)*

Cited by 57 publications

References 0 publications

1000 Port‐A‐Cath^® Placements by Subclavian Vein Approach: Single Surgeon Experience

1000 Port‐A‐Cath^® Placements by Subclavian Vein Approach: Single Surgeon Experience

Totally implantable venous access devices in cystic fibrosis: complications and patients' opinions

Double lumen port access in patients receiving allogeneic blood stem cell transplantation

Contact Info

Product

Resources

About

Comparison of a Totally Implantable Access Device for Chemotherapy (Port-A-Cath) and Long-term Percutaneous Catheterization (Broviac)*

Cited by 57 publications

References 0 publications

1000 Port‐A‐Cath® Placements by Subclavian Vein Approach: Single Surgeon Experience

1000 Port‐A‐Cath® Placements by Subclavian Vein Approach: Single Surgeon Experience

Totally implantable venous access devices in cystic fibrosis: complications and patients' opinions

Double lumen port access in patients receiving allogeneic blood stem cell transplantation

Contact Info

Product

Resources

About

1000 Port‐A‐Cath^® Placements by Subclavian Vein Approach: Single Surgeon Experience

1000 Port‐A‐Cath^® Placements by Subclavian Vein Approach: Single Surgeon Experience